[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2023, "totalPay": 1209900, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela Yanchik Connealy M.B.A.", "age": 62, "title": "CFO & COO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 709700, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 61, "title": "Senior VP & Chief Business Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sondra  Smyrnios", "title": "Head of Global Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shui  He Ph.D.", "title": "Head of Biometrics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9339, "open": 0.9362, "dayLow": 0.92, "dayHigh": 0.9734, "regularMarketPreviousClose": 0.9339, "regularMarketOpen": 0.9362, "regularMarketDayLow": 0.92, "regularMarketDayHigh": 0.9734, "payoutRatio": 0.0, "beta": 1.171, "forwardPE": -0.80949575, "volume": 284743, "regularMarketVolume": 284743, "averageVolume": 550324, "averageVolume10days": 437070, "averageDailyVolume10Day": 437070, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 59330032, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": 3.6745963, "fiftyDayAverage": 1.1217, "twoHundredDayAverage": 2.487975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -47400952, "profitMargins": 0.0, "floatShares": 44339556, "sharesOutstanding": 61590400, "sharesShort": 7336969, "sharesShortPriorMonth": 7008856, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.1191, "heldPercentInsiders": 0.23723, "heldPercentInstitutions": 0.40065, "shortRatio": 15.1, "shortPercentOfFloat": 0.1436, "impliedSharesOutstanding": 61590400, "bookValue": 2.014, "priceToBook": 0.47830188, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -77331000, "trailingEps": -1.32, "forwardEps": -1.19, "enterpriseToRevenue": -2.936, "enterpriseToEbitda": 0.757, "52WeekChange": -0.78741723, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 0.9633, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.0, "targetMedianPrice": 5.5, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 126931000, "totalCashPerShare": 2.061, "ebitda": -62588000, "totalDebt": 20200000, "quickRatio": 7.179, "currentRatio": 7.491, "totalRevenue": 16146000, "debtToEquity": 16.729, "revenuePerShare": 0.276, "returnOnAssets": -0.24768999, "returnOnEquity": -0.62755, "grossProfits": 15671000, "freeCashflow": -33791248, "operatingCashflow": -57672000, "grossMargins": 0.97058, "ebitdaMargins": 0.0, "operatingMargins": -4.06107, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Pyxis Oncology, Inc.", "marketState": "CLOSED", "shortName": "Pyxis Oncology, Inc.", "corporateActions": [], "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.148088, "regularMarketPrice": 0.9633, "postMarketTime": 1744933197, "regularMarketTime": 1744920001, "firstTradeDateMilliseconds": 1633699800000, "postMarketChangePercent": -0.0207592, "postMarketPrice": 0.9631, "postMarketChange": -0.000199974, "regularMarketChange": 0.029399991, "regularMarketDayRange": "0.92 - 0.9734", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 550324, "fiftyTwoWeekLowChange": 0.13029999, "fiftyTwoWeekLowChangePercent": 0.15642256, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -4.4266996, "fiftyTwoWeekHighChangePercent": -0.8212801, "fiftyTwoWeekChangePercent": -78.74172, "earningsTimestamp": 1742297400, "earningsTimestampStart": 1747053000, "earningsTimestampEnd": 1747398600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.32, "epsForward": -1.19, "epsCurrentYear": -1.15333, "priceEpsCurrentYear": -0.8352336, "fiftyDayAverageChange": -0.15840006, "fiftyDayAverageChangePercent": -0.14121428, "twoHundredDayAverageChange": -1.5246749, "twoHundredDayAverageChangePercent": -0.61281765, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]